India on Tuesday approved emergency use authorisation of Covid-19 vaccines Covovax, Corbevax, and an anti-viral drug Molnupiravir, informed Union Health Minister Dr Mansukh Mandaviya.
Mansukh Mandaviya tweeted: "Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare has given emergency use authorization approval to Covid-19 vaccines Covovax & Corbevax and Anti-viral drug Molnupiravir."
Further elaborating on the CORBEVAX vaccine, the Minister said that it is the first indigenously developed RBD protein sub-unit vaccine against Covid-19.
"CORBEVAX vaccine is India's 1st indigenously developed RBD protein sub-unit vaccine against #COVID19, Made by Hyderabad-based firm Biological-E. It's a hat-trick! It's now 3rd vaccine developed in India!" the Minister tweeted.
"The Nanoparticle Vaccine, COVOVAX, will be manufactured by Pune-based firm Serum Institute of India," Mandaviya further added in the tweet.
The Minister informed that the antiviral drug, Molnupiravir will be used for emergency situations for the treatment of adult patients with Covid-19 and who have a high risk of progression of the disease.
"Molnupiravir, an antiviral drug, will now be manufactured in the country by 13 companies for restricted use under emergency situation for treatment of adult patients with COVID-19 and who have a high risk of progression of the disease," he tweeted.
The Minister said that all these approvals will further strengthen the global fight against the pandemic adding that India's Pharma Industries are asset for the entire world.
Earlier, India had developed Covaxin, the first indigenously developed Covid-19 vaccine which was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) National Institute of Virology.